Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12782574)

  • 1. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
    Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
    Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
    Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
    Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
    Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
    Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological prevention of a multigene cancer syndrome.
    Croci S; Nicoletti G; Landuzzi L; De Giovanni C; Astolfi A; Marini C; Di Carlo E; Musiani P; Forni G; Nanni P; Lollini PL
    Cancer Res; 2004 Nov; 64(22):8428-34. PubMed ID: 15548714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
    Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and Her-2/neu in juvenile angiofibromas.
    Schick B; Veldung B; Wemmert S; Jung V; Montenarh M; Meese E; Urbschat S
    Oncol Rep; 2005 Mar; 13(3):453-7. PubMed ID: 15706416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
    Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
    Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
    Izzotti A; Cartiglia C; Longobardi M; Bagnasco M; Merello A; You M; Lubet RA; De Flora S
    Cancer Res; 2004 Dec; 64(23):8566-72. PubMed ID: 15574763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
    Jochum W
    Verh Dtsch Ges Pathol; 2004; 88():224-30. PubMed ID: 16892556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inactivation of p53 in human cells does not result in aneuploidy.
    Bunz F; Fauth C; Speicher MR; Dutriaux A; Sedivy JM; Kinzler KW; Vogelstein B; Lengauer C
    Cancer Res; 2002 Feb; 62(4):1129-33. PubMed ID: 11861393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 family members in myogenic differentiation and rhabdomyosarcoma development.
    Cam H; Griesmann H; Beitzinger M; Hofmann L; Beinoraviciute-Kellner R; Sauer M; Hüttinger-Kirchhof N; Oswald C; Friedl P; Gattenlöhner S; Burek C; Rosenwald A; Stiewe T
    Cancer Cell; 2006 Oct; 10(4):281-93. PubMed ID: 17045206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.
    Tsumura H; Yoshida T; Saito H; Imanaka-Yoshida K; Suzuki N
    Oncogene; 2006 Dec; 25(59):7673-9. PubMed ID: 16785989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
    Hayakawa Y; Rovero S; Forni G; Smyth MJ
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9464-9. PubMed ID: 12867593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
    Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.